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Extracellular vesiclesCoagulation is initiated by tissue factor (TF). Coagulant TF is constitutively expressed by extravascular cells,
but there is increasing evidence that TF can also be present within the blood, in particular during pathological
conditions. Such TF is exposed on circulating cell-derived vesicles, and its presence has been associated with
development of disseminated intravascular coagulation and venous thrombosis. For example, the presence of
TF-exposing vesicles in the blood of cancer patients may be associated with their high risk of developing ve-
nous thromboembolism. Remarkably, high levels of coagulant TF-exposing vesicles are present in other body
ﬂuids such as saliva and urine of healthy persons, suggesting that these vesicles play a physiological role. We
postulate that the presence of TF-exposing vesicles in body ﬂuids as saliva and urine provides an additional
source of coagulant TF that promotes coagulation, thereby reducing blood loss and contributing to host de-
fence by reducing the risk of microorganisms entering the “milieu intérieur”.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Body ﬂuids such as blood contain not only cells but also more than
10 billion vesicles per mL. These vesicles, i.e. microparticles and
exosomes, are spherical particles enclosed by a phospholipid bilayer
which are released by cells. The diameter of extracellular vesicles ranges
between 30 nmand 1 μm.Vesicles have gained a strong clinical interest
because they have many functions, e.g. they initiate blood clotting and
promote inﬂammation, facilitate intercellular communication, modu-
late the immune system, protect cells from waste accumulation and
contribute to (multi) drug resistance. Moreover, vesicles differ in con-
centration, composition and function in diseases as cancer, diabetes
and cardiovascular disease compared to healthy subjects, and therefore
vesicles have been evaluated for their use as biomarkers [1]. At present,
research in the ﬁeld of cell-derived vesicles is developing rapidly. In this
brief overview, we will provide an overview on the role of tissue factor
(TF) exposing vesicles in thrombosis and host defence.Vesicles and thrombosis
The mechanisms by which cell-derived vesicles contribute to
coagulation and thrombosis were elucidated already in the early
1980's. A pioneering study of Dvorak and co-workers showedf the University of Amsterdam,
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ciated with membrane vesicles. They postulated that these vesicles
(i) provide a phospholipid surface to allow assembly of tenase and
prothrombinase complexes, and (ii) exhibit a ‘thromboplastin-like’
activity, i.e. a tissue factor activity [2]. Later studies conﬁrmed both
hypotheses [3,4]. Thus, TF does not only have an extravascular distri-
bution, but can also be present within the blood where TF is associat-
ed with cell-derived vesicles [5–8]. Injection of TF-exposing vesicles
in animals triggers (TF-dependent) thrombus formation, illustrating
that such vesicles are indeed highly procoagulant in vivo [9]. There
are four remarks to be made. First, TF exposed on circulating vesicles
in human blood is not necessarily coagulant. For example, plasma
from patients with diabetes type II contains elevated levels of vesi-
cles exposing TF compared to controls, but these vesicles do not in-
duce TF-dependent coagulation in vitro [10]. Second, coagulant
TF-exposing vesicles are removed from circulating human blood by ex-
tremely efﬁcient clearancemechanisms.Whenwoundblood of patients
undergoing open heart surgery, which contains high numbers of coag-
ulant TF-exposing vesicles, is returned into the systemic circulation,
the coagulant activity that is associated with these vesicles is removed
from the systemic blood within 20 to 30 minutes [11]. Third,
TF-exposing vesiclesmay interactwith platelets adhered to a site of vas-
cular injury, thereby delivering coagulant TF “on the spot” [12].
Cancer: TF, vesicles, and thrombosis?
Venous thromboembolism (VTE) is a common complication in
cancer patients and the second leading cause of in-hospital mortality
[13]. The procoagulant phenotype is characterised by increased
S72 A. Kleinjan et al. / Thrombosis Research 130 (2012) S71–S73plasma concentrations of activated (coagulation) factor VII and TF
compared to controls, indicating activation of extrinsic (TF-initiated)
coagulation [14]. This TF may originate from the tumour, because dif-
ferent types of cancer cells express and produce TF [15,16]. This TF is
at least in part released on vesicles [2–4], which in turn may enter the
blood [17]. Further evidence that such vesicles may contribute to VTE
comes from ﬁndings that (i) plasma from cancer patients contains in-
creased numbers of TF-exposing vesicles (compared to controls)
[18,19], (ii) the TF coagulant activity that is associated with vesicles
is elevated in cancer patients [20,21], (iii) cancer patients who devel-
oped VTE have higher numbers of TF-exposing vesicles and an elevat-
ed TF coagulant activity associated with these vesicles than cancer
patients without VTE [22–25].
Although VTE is clearly a complication occurring in many cancer
patients, treating all cancer patients with prophylactic doses of
anti-coagulant therapy to prevent VTE is unattractive due to the
risk of bleeding. Therefore, in 2010 we have initiated a study to in-
vestigate whether cancer patients at risk of developing VTE can be
identiﬁed. We hypothesize that such high risk patients have elevat-
ed numbers of coagulant TF-exposing vesicles already before the onset
of VTE. In this study, blood is collected from cancer patients before a
new gift of chemotherapy, and we perform a vesicle-based coagulation
assay, a plasma recalciﬁcation test inwhich the clotting time dependent
on both phosphatidylserine and TF [21,26]. Our pilot data conﬁrmed our
hypothesis [21], and this study is now ongoing in eight hospitals and
more than 600 patients have already been included.
Recently,Wang and co-workers showed in nudemice that although
two human pancreatic tumour cell lines produce comparable numbers
of TF-exposing vesicles, only one cell line produced detectable levels
of vesicles-associated TF coagulant activity, implicating that there is
no direct relationship between MP-associated TF antigen and activity
[27]. Thus, the relationship between the presence of TF-exposing vesi-
cles in plasma and the TF-dependent coagulant activity of vesicles in
cancer patients is unclear. This is conﬁrmed by a nearly completed
study in Amsterdam, in which we measured both the presence of
MP-associated TF antigen and TF coagulant activity in plasma samples
collected from over 200 cancer patients. We found no association be-
tween TF antigen and activity. For example, plasma samples clearly
containing a TF coagulant activity contained no detectable numbers of
vesicles exposing TF (A. Kleinjan, manuscript in prep.), suggesting that
either minute quantities of coagulant TF are sufﬁcient to trigger coagu-
lation, and/or that TF is associated with vesicles with a diameter too
small to be detected by ﬂow cytometry [28].
To which extent coagulant TF-exposing vesicles that are present in
plasma of cancer patients originate from the tumour is unclear. We
determined the cellular origin in cancer patients who had numbers
of TF-exposing vesicles above the >95th percentile in the before
mentioned study. In 5 patients, TF-exposing vesicles stained for
both tumour markers and markers of blood cells, and in these pa-
tients more than 100% of the vesicles were labelled, indicating fusion
of vesicles or transfer of TF between vesicles and/or cells. In 8 other
patients, however, only 30% of the vesicles exposed blood cell anti-
gens but no detectable levels of tumour antigens, and the cellular or-
igin of the other 70% of TF-exposing vesicles could not be established
(A. Kleinjan, manuscript in prep.). Thus, to which extent coagulant TF
that is associated with circulating vesicles in blood of cancer patients
originates from the tumour remains unclear. The fact that plasma
samples containing the highest levels of TF coagulant activity contain
no detectable levels of TF-exposing vesicles clearly illustrates that ad-
ditional studies will be essential to elucidate the cellular origin of ves-
icles exposing coagulant TF in cancer patients.
TF-exposing vesicles in body ﬂuids other than blood
In essence, coagulation and inﬂammation are processes that con-
tribute to host defence. Coagulation contributes to haemostasis, thusreducing blood loss andminimizing the risk of microorganisms enter-
ing the “milieu intérieur”. Under normal, physiological conditions vir-
tually no coagualant TF is associated with circulating vesicles. When
such TF is present, this TF is associated with e.g. bleeding as in dis-
seminated intravascular coagulation, or with VTE as in cancer pa-
tients. Recently, we showed that saliva of healthy humans subjects
contains high levels of vesicles exposing coagulant TF that is capable
of triggering the clotting of blood [26]. We therefore hypothesized
that the reﬂex of humans and animals to lick a wound may – at
least in part – be explained by the presence of such vesicles in saliva.
Because also urine from healthy human subjects contains a clearly de-
tectable TF coagulant activity that is associated with vesicles, we pos-
tulate that the presence of such vesicles in body ﬂuids which are in
contact with the epithelium and the “milieu exteriéur”may be associ-
ated with haemostasis, host defence and thus contribute to mainte-
nance and survival of an organism.
Conclusion
The presence of vesicles exposing coagulant TF depends on the
type of body ﬂuid studied, and whether the ﬂuid is collected from
healthy persons or from patients. Whereas vesicles exposing coagu-
lant TF in saliva and urine are likely to contribute to host defence,
i.e. protection of the “milieu interiéur”, the presence of such vesicles
in blood seems to be associated with disease or disease progression.
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